Last month, Demis Hassabis and John Jumper of Google DeepMind were jointly awarded the 2024 Nobel Prize in Chemistry for their development of AlphaFold 3. This AI model can more accurately predict the ...

Add Yahoo as a preferred source to see more of our stories on Google. In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s ...

(Bloomberg) -- Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive ...

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system ...

Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...

Proteins are the microscopic workhorses of the human body, driving everything from oxygen transport to muscle contraction. Their complex 3D structures dictate their function, and understanding these ...

Demis Hassabis and John Jumper are the developers behind AlphaFold, an algorithmic model that can predict the 3D shape of proteins from their amino acid sequences. The model lets researchers visualize ...

On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...

In this episode of ET@Davos, ET’s Sruthijith KK speaks to Demis Hassabis, CEO of Google DeepMind and Nobel Laureate 2024, on the future of AI. The chess prodigy-turned scientist-turned-AI pioneer ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...